PARAMOUNT trial

PARAMOUNT Trial is a clinical trial that was conducted to evaluate the efficacy and safety of Pemetrexed as a maintenance therapy for patients with advanced Non-small cell lung cancer (NSCLC) who have not progressed after initial chemotherapy. The trial was a phase III, double-blind, placebo-controlled study.

Overview

The PARAMOUNT trial was designed to assess the benefits of maintenance therapy with Pemetrexed in patients with advanced NSCLC who had not progressed after four cycles of Pemetrexed-cisplatin induction therapy. The primary endpoint of the trial was progression-free survival, while secondary endpoints included overall survival, response rate, and safety.

Results

The results of the PARAMOUNT trial showed that maintenance therapy with Pemetrexed significantly improved progression-free survival in patients with advanced NSCLC. The trial also demonstrated a trend towards improved overall survival, although this was not statistically significant.

Implications

The findings of the PARAMOUNT trial have important implications for the management of patients with advanced NSCLC. They suggest that maintenance therapy with Pemetrexed may be a viable option for these patients, potentially improving their quality of life and survival outcomes.

See Also

• Clinical trial
• Non-small cell lung cancer
• Pemetrexed
• Chemotherapy

References

• PARAMOUNT trial informed consent document
  PARAMOUNT trial informed consent document
• Diagram of human lungs
  Diagram of human lungs